Subject compensation [Study Per­for­mance]

posted by roody – 2006-02-06 10:41 (7436 d 18:06 ago) – Posting: # 75
Views: 9,200

Hi shiv,

I think this should be decided by the IRB/IEC. There may be difference in opinion when you consider institute to that of IEC members. IRB may not agree for fixing value for human blood.

Regards,
Rudolph

❝ Benifits should be proportionate to the risks involved in the study.


❝ The subject compensation should be proportionate to the risks involved in

❝ the study (such as duration of the stay, adverse events, number of sample

❝ points, volume of the blood, number of ambulatory samples etc.,).


Edit: Full quote removed. [HS]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
167 visitors (0 registered, 167 guests [including 21 identified bots]).
Forum time: 05:48 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5